R & D

TAU BIO-LOGIC CORPORATION is focused on the development of innovative high precision immunotherapies for the treatment of tauopathies such as Alzheimer’s disease (AD) and Progressive Supranuclear Palsy (PSP).  Its patented platform relates to the development of monoclonal antibodies (mAbs) targeting neurotoxic tau protein fragments, especially tauC3, with mAbs that do not bind to full length tau (FLT).  TAU BIO-LOGIC’s approach and lead candidate, TBL-100,  offer several key advantages compared to other tau immunotherapies  in development:

  • Validated therapeutic target
    • Accounts for the majority of tau seeding activity in human AD brain
    • Major cause of intracellular neurotoxicity and neuronal dysfunction
    • Reversible effects in animal models
  • Picomolar affinity humanized mAbs with 1000-fold specificity compared to FLT
  • Demonstrated potential to block tau propagation in AD brain
  • Demonstrated potential for improved safety and efficacy
  • Strong IP portfolio including methods of treatment and composition of matter until 2040

TAU BIO-LOGIC is investing in the optimization of TBL-100 and aims to demonstrate safety, efficacy and dosing advantages versus competitors while also rapidly advancing the program toward the initiation of human clinical trials in patients.